Hims & Hers Health (NYSE:HIMS) PT Raised to $25.00 at Bank of America

Hims & Hers Health (NYSE:HIMS) had its target price lifted by stock analysts at Bank of America from $23.00 to $25.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price target would indicate a potential upside of 5.98% from the stock’s current price.

Other research analysts have also issued reports about the stock. TD Cowen increased their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Finally, Needham & Company LLC began coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and a consensus target price of $20.21.

Hims & Hers Health Stock Up 2.3 %

HIMS opened at $23.59 on Monday. The stock has a market cap of $5.07 billion, a PE ratio of -2,359.00 and a beta of 1.06. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $25.74. The company has a fifty day moving average of $17.08 and a 200-day moving average of $17.67.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.03) earnings per share. Sell-side analysts anticipate that Hims & Hers Health will post 0.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 269,739 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the sale, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the transaction, the chief financial officer now owns 145,763 shares in the company, valued at $2,960,446.53. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the completion of the transaction, the insider now owns 193,980 shares of the company’s stock, valued at $4,306,356. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 841,076 shares of company stock worth $14,759,219. Insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of HIMS. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock worth $126,142,000 after purchasing an additional 46,541 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Hims & Hers Health during the fourth quarter valued at approximately $155,000. Los Angeles Capital Management LLC grew its stake in Hims & Hers Health by 58.5% during the first quarter. Los Angeles Capital Management LLC now owns 28,206 shares of the company’s stock valued at $436,000 after acquiring an additional 10,405 shares in the last quarter. Counterpoint Mutual Funds LLC purchased a new position in Hims & Hers Health during the first quarter valued at approximately $285,000. Finally, State of Michigan Retirement System purchased a new position in Hims & Hers Health during the first quarter valued at approximately $2,785,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.